Turnstone Biologics
Turnstone Biologics is dedicated to developing innovative cancer immunotherapies, focusing on next-generation tumor infiltrating lymphocytes (TILs) and viral immunotherapy to treat solid tumors. Their mission is to create medicines that can cure patients with solid tumors, leveraging advanced scientific approaches and strategic collaborations to transform cancer treatment.
Industries
Nr. of Employees
medium (51-250)
Turnstone Biologics
9310 Athena Circle, Suite 300, La Jolla, CA 92037, USA
Patents
Products
TIDAL-01 (Selected TIL therapy)
An autologous selected and expanded tumor-infiltrating lymphocyte product designed to enrich for neoantigen- and tumor-reactive T cells for treatment of solid tumors; being evaluated in early-phase clinical trials.
RIVAL-01 (Oncolytic vaccinia viral immunotherapy)
A clinical-stage oncolytic vaccinia viral immunotherapy program engineered for enhanced tumor targeting, immune activation, and delivery of multiple payload transgenes to drive oncolysis and antitumor immunity; developed for combination with cell therapies.
TBio BFX 4101 (Neoantigen prioritization pipeline)
A computational and experimental pipeline for prioritizing tumor neoantigens to guide selection of tumor-reactive T cells for personalized TIL therapies.
TIDAL-01 (Selected TIL therapy)
An autologous selected and expanded tumor-infiltrating lymphocyte product designed to enrich for neoantigen- and tumor-reactive T cells for treatment of solid tumors; being evaluated in early-phase clinical trials.
RIVAL-01 (Oncolytic vaccinia viral immunotherapy)
A clinical-stage oncolytic vaccinia viral immunotherapy program engineered for enhanced tumor targeting, immune activation, and delivery of multiple payload transgenes to drive oncolysis and antitumor immunity; developed for combination with cell therapies.
TBio BFX 4101 (Neoantigen prioritization pipeline)
A computational and experimental pipeline for prioritizing tumor neoantigens to guide selection of tumor-reactive T cells for personalized TIL therapies.
Services
End-to-end development and execution of autologous Selected TIL manufacturing processes for clinical supply, including selection, expansion, lot release testing and transfer to CMOs.
Design and engineering of oncolytic vaccinia viral backbones optimized for tumor targeting, immune activation, and delivery of multiple transgenes to modulate antitumor immunity and enable combination approaches.
Computational and laboratory workflows to prioritize tumor neoantigens from whole-exome sequencing (including liquid biopsy) to inform selection of tumor-reactive T cells.
Development, qualification/validation and transfer of analytical assays for cell therapy characterization, lot release, in-process control and stability to support clinical manufacturing.
Manufacturing Science & Technology services including technology transfer execution, person-in-plant (PIP) support, process verification, root cause analysis, and process optimization for clinical operations.
Establish and manage collaborations with academic cancer centers, national institutes and industry partners to support translational research, investigator-sponsored trials, and early clinical development.
End-to-end development and execution of autologous Selected TIL manufacturing processes for clinical supply, including selection, expansion, lot release testing and transfer to CMOs.
Design and engineering of oncolytic vaccinia viral backbones optimized for tumor targeting, immune activation, and delivery of multiple transgenes to modulate antitumor immunity and enable combination approaches.
Computational and laboratory workflows to prioritize tumor neoantigens from whole-exome sequencing (including liquid biopsy) to inform selection of tumor-reactive T cells.
Development, qualification/validation and transfer of analytical assays for cell therapy characterization, lot release, in-process control and stability to support clinical manufacturing.
Manufacturing Science & Technology services including technology transfer execution, person-in-plant (PIP) support, process verification, root cause analysis, and process optimization for clinical operations.
Establish and manage collaborations with academic cancer centers, national institutes and industry partners to support translational research, investigator-sponsored trials, and early clinical development.
Expertise Areas
- Selected TIL therapy development
- Oncolytic viral immunotherapy
- Neoantigen discovery and prioritization
- Cell therapy manufacturing and CMC
Key Technologies
- Selected TIL isolation and expansion
- FACS-based cell sorting and multi-color flow cytometry
- Oncolytic vaccinia viral vector engineering
- Transgene payload delivery (cytokines, growth factors, checkpoint modulators)